Medicenna Therapeutics Corp.

Symbol: MDNA.TO




Market price today

  • -2.7357

    P/E Ratio

  • -0.0879

    PEG Ratio

  • 30.63M

    MRK Cap

  • 0.00%

    DIV Yield

Medicenna Therapeutics Corp. (MDNA-TO) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Fahar Merchant Ph.D.
Full-time employees:16
Address:2 Bloor Street West

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

General Outlook

In simple terms, Medicenna Therapeutics Corp. has 67.316 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.417% return, is a testament to Medicenna Therapeutics Corp.'s adeptness in optimizing resource deployment. Medicenna Therapeutics Corp.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.410%. Furthermore, the proficiency of Medicenna Therapeutics Corp. in capital utilization is underscored by a remarkable -0.702% return on capital employed.

Stock Prices

Medicenna Therapeutics Corp.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.48, while its low point bottomed out at $0.45. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Medicenna Therapeutics Corp.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Medicenna Therapeutics Corp. (MDNA.TO) on the TSX in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -2.736 in 2023.

What is the ticker symbol of Medicenna Therapeutics Corp. stock?

The ticker symbol of Medicenna Therapeutics Corp. stock is MDNA.TO.

What is company IPO date?

IPO date of Medicenna Therapeutics Corp. is 2017-03-08.

What is company current share price?

Current share price is 0.455 CAD.

What is stock market cap today?

The market cap of stock today is 30628879.000.

What is PEG ratio in 2023?

The current -0.088 is -0.088 in 2023.

What is the number of employees in 2023?

In 2023 the company has 16.